Winslow Brendan R. 4
4 · Atrium Therapeutics, Inc. · Filed Apr 22, 2026
Research Summary
AI-generated summary of this filing
Atrium (RNA) CFO Brendan Winslow Receives RSUs & Stock Options
What Happened
Brendan R. Winslow, Chief Financial Officer of Atrium Therapeutics, received compensation awards on April 20, 2026: 30,000 restricted stock units (RSUs) and a 60,000-share option grant (reported as a derivative acquisition). Both awards were granted at $0.00 (i.e., no cash paid). These are grants/awards (not open‑market purchases or sales).
Key Details
- Transaction date: April 20, 2026; Form 4 filed April 22, 2026 (timely, within the typical two‑business‑day reporting window). Accession: 0001193125-26-170960.
- RSUs: 30,000 RSUs granted at $0.00. (Footnote F1)
- Options/derivative: 60,000 shares granted as a derivative security at $0.00. (Footnote F2)
- Shares owned after the transaction: not specified in the filing.
- No 10b5-1 plan, tax‑withholding, or sale noted in this filing.
- Footnotes: F1 explains each RSU converts to one share upon vesting; 25% vests March 20, 2027, then three equal annual installments thereafter, subject to continued service. F2 explains option vesting: 25% vests March 20, 2027, then the remainder vests in 36 substantially equal monthly installments, subject to continued service.
Context RSUs are a contingent right to receive company shares once vested; stock options give the right to buy shares in the future if the holder exercises. Both awards are common forms of executive compensation intended for retention and alignment with shareholders; they do not involve an immediate cash outlay or sale of shares and should not be interpreted alone as a buy/sell signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-04-20+30,000→ 43,601 total - Award
Stock Option (Right to Buy)
[F2]2026-04-20+60,000→ 60,000 totalExercise: $14.30Exp: 2036-04-20→ Common Stock (60,000 underlying)
Footnotes (2)
- [F1]Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
- [F2]Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.